Clinical Data Summit Therapeutics announced additional positive data from its Phase 2 CoDIFy clinical trial that shows the narrow spectrum antibiotic ridinilazole preserves the gut microbiome in CDI patients.  Other treatments, including the standard of care vancomycin, cause "ubstantial and long-lasting damage on the gut microbiome".  The clinical data strongly suggest that ridinilazole treatment may be better able to protect against recurrent disease than the current standard of care," commented Glyn Edwards, Chief Executive Officer of Summit Therapeutics.